As of 2026-09-16, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -6.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 91.52 mil USD. OCX's TTM EBITDA according to its financial statements is -14.41 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.9x - 16.6x | 16.1x |
| Forward P/E multiples | 18.3x - 20.1x | 19.5x |
| Fair Price | (9.22) - (8.36) | (8.97) |
| Upside | -388.2% - -361.1% | -380.3% |
| Date | EV/EBITDA |